Abstract Controlled human infection models (CHIM) provide a crucial platform for evaluating influenza countermeasures. This dose-escalation, double-blind, randomized, placebo-controlled study aimed to establish the optimal infectious dose of a recombinant influenza A/Texas/71/2017 (H3N2) challenge strain. Healthy adults aged 18–45 received sham inoculum or 10⁴, 10⁵, or 10⁶ median tissue culture infectious dose (TCID₅₀) of challenge virus and were monitored for 7 days.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile